)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Celltrion
Celltrion (068270) investor relations material
Celltrion Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
3Q26 sales reached a quarterly record KRW 1,575.5bn, up 53.1% YoY; operating profit also hit a record KRW 525.3bn, up 74.3% YoY.
Growth was led by Young Products, whose 3Q26 sales rose 74% YoY and represented 67% of biologics sales; higher-margin products also supported a 33.3% operating margin.
Financial highlights
9M26 sales were KRW 4,114bn, up 45.3% YoY; operating profit was KRW 1,299bn, up 87.4%, and net profit was KRW 800bn, up 58.8%.
3Q26 gross profit was KRW 955bn and gross margin 60.6%; operating margin was 33.3%, versus 29.3% in 3Q25.
3Q26 net profit was KRW 78bn, versus KRW 332bn in 3Q25; profit before income tax was KRW 103bn, versus KRW 378bn.
Outlook and guidance
4Q sales growth and margin improvement are expected to continue, supported by Young Products and geographic expansion; Young Products’ revenue share is projected to exceed 70% in 4Q.
Five products launched in 2025 generated KRW 388bn of 3Q26 revenue; continued ramp-up, new markets and indication expansion are expected to support growth through 4Q26 and 2027.
Biosimilar portfolio targets: 18 commercialized products by 2030 and 41 by 2038; plans also include obesity-treatment IND filings and CT-P77 preclinical results and IND submission by year-end.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Celltrion
- Biosimilar growth and merger integration set an ambitious 2024 outlook, despite profit pressure.068270
Q4 2023 - Portfolio expansion, Zymfentra and AI-enabled R&D anchor the growth roadmap.068270Investor presentation
- Record 2Q24 sales and expanding biosimilar and novel-drug growth plans.068270Investor presentation
- Zymfentra and pipeline growth pair with CDMO expansion and higher shareholder returns.068270Investor presentation
- A broad biosimilar base supports an ADC and multispecific antibody pipeline advancing toward 2028 INDs.068270Investor presentation
- Targets combine rapid product expansion, higher profitability and 40% average shareholder returns.068270Investor presentation
- 2025 targets combine KRW 5T revenue with sharply lower COGS and stronger operating profit.068270Investor presentation
- Young products fuel 1Q growth as FY25 sales are forecast to reach KRW 5tn.068270Investor presentation
- Young-product growth lifted 3Q25 profit as biosimilar launches and capacity expanded.068270Investor presentation
- Young biologics drove 2Q25 profit growth as five launches target a larger market.068270Investor presentation
Next Celltrion earnings date
Q4 202616 Mar, 2027
Celltrion
Next Celltrion earnings date
Q4 202616 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Celltrion Inc. is a South Korea-based biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company focuses on monoclonal antibodies, biosimilars, and innovative biologic therapies for various medical conditions. Celltrion operates state-of-the-art biopharmaceutical production facilities and engages in global partnerships for the commercialization of its products. The company is headquartered in Incheon, South Korea, and its shares are listed on the KRX.